Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This project is a pilot, phase II, open-label, single-center, non-comparative clinical study
evaluating the antitumor efficacy and tolerability of exemestane in treating adult
post-menopausal women with recurrent or refractory, stage II-IV, epithelial ovarian cancer.
To evaluate the efficacy and tolerability of exemestane in this population, patients will be
enrolled at a single site, namely the Ottawa Regional Cancer Center. Patients selected
according to the criteria outlined will receive exemestane (25 mg/day given orally once
daily) until disease progression or until study withdrawal. These patients will be treated on
an out-patient basis. There is no specific wash-out time required for patients who have
previously received either cis or carboplatinum; however, this previous therapy must stop
upon patient inclusion into this trial.
In 1st stage if less than 2/15 patients achieve a response then study will be terminated. In
2nd stage if greater than 7/28 patients achieve a response then no further investigation of
the drug is warranted.Treatment (including drug dosages) A commercial supply of exemestane
(Aromasin) will be provided. The medication will be administered by the patient at home (25
mg taken orally once daily until disease progression) The medication should be taken each day
after a meal at the same time of the day. There are no patient diaries and no need for the
patient to record the time of administration.